Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471714 | 0.82 | CHRM2 (0.38) | CHRM2CHRM3KDM4EALDH1A1GAA | |
| SCHEMBL20599068 | 0.82 | NOTUM (0.46) | CHRM2CHRM3KDM4EALDH1A1GAA | |
| SCHEMBL21471717 | 0.81 | MAPK14 (0.41) | CHRM2CHRM3KDM4EALDH1A1GAA | |
| SCHEMBL21474620 | 0.81 | MAPK14 (0.41) | CHRM2CHRM3KDM4EALDH1A1GAA | |
| SCHEMBL21471733 | 0.79 | NOTUM (0.33) | KDM4EALDH1A1GAAL3MBTL1NOTUM | |
| SCHEMBL20619490 | 0.79 | ALDH1A1 (0.50) | CHRM2CHRM3KDM4EALDH1A1GAA | |
| SCHEMBL21471675 | 0.78 | ALDH1A1 (0.47) | CHRM2CHRM3ARKDM4EALDH1A1 | |
| SCHEMBL21471683 | 0.78 | CHRM2 (0.36) | CHRM2CHRM3ARKDM4EALDH1A1 | |
| SCHEMBL21471679 | 0.78 | AVPR2 (0.35) | ALDH1A1GAA | |
| SCHEMBL20622402 | 0.78 | HPGD (0.42) | CHRM2CHRM3KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | CHRM2 3915/4885CHRM3 2654/4885AR 4319/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | CHRM2 3915/4885CHRM3 2654/4885AR 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.